Suicide risk and symptom reduction in patients assigned to placebo in Duloxetine and Escitalopram clinical trials: analysis of the FDA summary basis of approval reports

Khan A, Schwartz K. Annals of clinical psychiatry 2007; 19(1):31-36

ARTICLE IDENTIFIERS

DOI: 10.1080/10401230601163550

PMID: 17453659 PMCID: not available

JOURNAL IDENTIFIERS

LCCN: not available pISSN: 1040-1237 eISSN: 1547-3325 OCLC ID: not available CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.